נפח מכירות החברה affimed.com (AFMD)

Demand for lymphoma treatment remains stable and independent of macroeconomic conditions, as confirmed by Affimed (AFMD) actual sales. The value of 0.00 determines the current status of the parameter. Revenue growth is driven by partner payments and the success of "engager" antibody tests. To strengthen its position, Affimed is reducing costs, focusing on NK cells and seeking new B2B alliances within the immuno-oncology sector.

For an investor in Affimed (AFMD), which develops innovative immunotherapy for oncology centers, this indicator serves as a tool to verify actual commercial demand for anti-tumor drugs. By analyzing the company's sales efficiency, we track daily cash inflows from clients, allowing us to distinguish fundamental revenue growth from speculative momentum and assess the sustainability of the business model within the targeted drug segment.